Trends in utilization and Medicare spending on short-course radiation therapy for breast and prostate cancer: An episode-based analysis from 2015 to 2019
Purpose Evidence supports the value of shorter, similarly efficacious, and potentially more
cost-effective hypofractionated radiation therapy (RT) regimens in many clinical scenarios …
cost-effective hypofractionated radiation therapy (RT) regimens in many clinical scenarios …
Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma.
RJ Cruz-Chamorro, A Gan… - … in Oncology & …, 2024 - search.ebscohost.com
Advanced Merkel cell carcinoma (MCC) is an unresectable, recurrent or metastatic and
aggressive cancer with 5-year survival rates between 20 and 30%. Historically …
aggressive cancer with 5-year survival rates between 20 and 30%. Historically …